10 patents currently held
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Jun 2030. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
5
Ending by 2030
Jun 2030
Next term end
2
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 2 of the currently held patents qualify as notable.
Notable
Ends Jun 2030 · Low confidence
Also notable
Ends Jan 2036 · High confidence
Formulations Comprising Triptan Compounds
US 9,610,280
The most cited patent in this portfolio, cited by 13 later US patents, top 25% of utility patents granted in 2017 in our data. Protection runs to 2030. A terminal disclaimer caps this term to an earlier patent's.
Pharmaceutical Composition for Treating Migraine
US 10,537,554
Granted 2020. Computed term ends 2036.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jun 15, 2027The maintenance fee for Formulations Comprising Triptan Compounds (US 9,211,282) comes due Jun 15, 2027. Unpaid by Dec 15, 2027, it lapses early.
- 1 fee due Jul 21, 2027The maintenance fee for Pharmaceutical Composition for Treating Migraine (US 10,537,554) comes due Jul 21, 2027. Unpaid by Jan 21, 2028, it lapses early.
- 1 fee due Sep 30, 2027The maintenance fee for Formulations Comprising Triptan Compounds (US 10,603,305) comes due Sep 30, 2027. Unpaid by Mar 31, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Formulations Comprising Triptan Compounds | 6 in force | to Jul 2031 |
| Pharmaceutical Composition for Treating Migraine | 4 in force | to Jan 2036 |
Patents held now
Soonest term end first.
Showing 1 to 10 of 10
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,610,280 | Formulations Comprising Triptan Compounds In force · Low confidence | In force | Low confidence | |
| US 9,974,770 | Formulations Comprising Triptan Compounds In force · Low confidence | In force | Low confidence | |
| US 10,603,305 | Formulations Comprising Triptan Compounds In force · Medium confidence | In force | Medium confidence | |
| US 11,337,962 | Formulations Comprising Triptan Compounds In force · Low confidence | In force | Low confidence | |
| US 12,090,139 | Formulations Comprising Triptan Compounds In force · Medium confidence | In force | Medium confidence | |
| US 9,211,282 | Formulations Comprising Triptan Compounds In force · Medium confidence | In force | Medium confidence | |
| US 10,537,554 | Pharmaceutical Composition for Treating Migraine In force · High confidence | In force | High confidence | |
| US 11,364,224 | Pharmaceutical Composition for Treating Migraine In force · High confidence | In force | High confidence | |
| US 12,097,183 | Pharmaceutical Composition for Treating Migraine In force · High confidence | In force | High confidence | |
| US 12,673,040 | Pharmaceutical Composition for Treating Migraine In force · Low confidence | In force | Low confidence |
Also on record, not counted in the 10: 2 applications pending · 1 application abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
1 terminal disclaimer is on file with no resolved reference. No cap is applied and none is guessed